Search Within

Anas Younes

  1. "Alison Moskowitz"
Formats
  1. Meeting Abstract (40)
  2. Journal Article (24)
  3. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (65)
  2. Department of Medicine (65)
  3. Executive Committee, Center for Hematologic Malignancies (65)
  4. Hematologic Malignancies, Division of (65)
  5. Lymphoma (65)
  6. Survivorship Research (60)

More Groups

People
  1. Alison Moskowitz (65)
  2. Andrew Zelenetz (60)
  3. Matthew Matasar (60)
  4. Paul Hamlin (58)
  5. David Straus (55)
  6. Steven Horwitz (55)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (5)
  4. 2021 (5)
  5. 2020 (8)
  6. 2019 (13)

More Years

Publications
  1. Blood (28)
  2. Hematological Oncology (10)
  3. Blood Cancer Journal (5)
  4. Blood Advances (4)
  5. Journal of Clinical Oncology (4)
  6. Haematologica (3)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. Wiley Blackwell (10)
  3. Nature Publishing Group (5)
  4. American Society of Clinical Oncology (4)
  5. Ferrata Storti Foundation (3)
  6. American Association for Cancer Research (2)

More Publishers

Results (65)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma
    Journal Article

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Gerecitano, J. F.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Expectant management of extranodal marginal zone lymphoma of bronchial-associated lymphoid tissue (BALT)
    Meeting Abstract

    Leyfman, Y.; Joffe, E.; Drill, E.; Rajeeve, S.; Zelenetz, A. D.; Palomba, M. L. L.; Moskowitz, C. H.; Portlock, C. S.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Seshan, V.; Noy, A.; Horwitz, S. M.; Palomba, M. L.; Matasar, M. J.; Straus, D. J.; Hamlin, P. A.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution
    Meeting Abstract

    Joffe, E.; Kumar, A.; Zheng, S.; Uppal, M.; Bantilan, K. S.; Atteberry, P.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution
    Meeting Abstract

    Joffe, E.; Kumar, A.; Zheng, S.; Uppal, M.; Bantilan, K. S.; Atteberry, P.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save